Pietro R Di Ciaccio's research while affiliated with Australian National University and other places

... Health care experiences of women diagnosed with LIP (during pregnancy or within 12 months postpartum) were analyzed through qualitative analysis of semistructured interviews. This study was a qualitative substudy of an Australasian Lymphoma Alliance (ALA) project on lymphoma in pregnancy in Australasia [13] and was approved by the St Vincent's Health Human Research Ethics Committee, Sydney (2020/ETH00489). The study adhered to the Consolidated Criteria for Reporting Qualitative Studies (COREQ) checklist (Supplementary Appendix 1) [14]. ...

... Furthermore, there is limited evidence defining reference ranges in pregnant women for laboratory markers relevant to the recognition, diagnosis, and prognostication of cancers [35]. Finally, physicians may be hesitant to request investigations (e.g., imaging investigations) that may potentially impact the fetus [36][37][38]. ...

... The initial diagnosis of cancer during pregnancy can be challenging as signs and symptoms of cancer can be incorrectly attributed to the pregnancy [3]. Furthermore, there is limited evidence defining reference ranges in pregnant women for laboratory markers relevant to the recognition, diagnosis, and prognostication of cancers [35]. Finally, physicians may be hesitant to request investigations (e.g., imaging investigations) that may potentially impact the fetus [36][37][38]. ...

... Patients with suspected or confirmed prior COVID-19 infection should be vaccinated according to international guidelines, as immunity may decrease over time [108]. ...

... Whereas these retrospective data only describe incidences of clinical reactivations of herpesviridae, introducing oral acyclovir (400 mg QID given from the start of therapy until four weeks after the last therapy cycle) together with cotrimoxazol (2 double strength doses twice a week) in addition to oral ciprofloxacin (500 mg BID) as anti-infective prophylaxis in the OPTIMAL > 60-trial significantly reduced grade 3/4 infections of all kind (from 28 to 18% per patient, p = 0.004) and treatment-related mortality (from 7 to 2%, p = 0.003) in elderly patients with DLBCL compared to a historical control [91]. Antiviral prophylaxis was also shown to reduce the risk of clinical reactivations of VZV and HSV in patients with indolent lymphomas treated with bendamustine ± anti-CD20 monoclonal antibody [92]. This evidence supports the use of pharmacological prophylaxis to reduce particularly VZV disease in non-Hodgkin lymphoma patients treated with (immuno-)chemotherapy (BIIu) ( Table 7). ...

... Extraoral disease has been reported in 43% of cases in a review of 248 patients (110) including the gastrointestinal tract, bone and skin. It is now seen outside of HIV-positive cohorts (111). Malignant cells have plasmablastic morphology and express a plasma cell-like immunophenotype (expression of CD38, CD138, MUM1, the antigen detected by the VS38c antibody, frequently CD79a, variably CD30, with a loss of CD20) and high Ki-67, usually above 90% (112). ...

... Anti-PP1P k can cause hemolytic transfusion reactions, and has the potential to cause severe, even fatal, hemolytic disease of the fetus and newborn. 4 Women with anti-PP1P k are at a higher risk for miscarriage, 5 likely due to the high expression of P1PK system antigens on the placenta with only low levels on fetal RBCs. We investigated the samples of two Bangladeshi sisters (S1 and S2), both obstetrics patients, referred with anti-PP1P k and a history of spontaneous abortion. ...

... Our study failed to demonstrate a reduction in cancer-related presentations; however, it did show that up to 76.1% of patients referred to the CUAC service potentially avoided an ED presentation. The avoidance of the ED by patients with cancer during the COVID-19 pandemic is a strategy recommended by expert groups through the application of screening algorithms or questionnaires [29,30]. Whilst the CUAC model of care was initially implemented to reduce the risk of exposure to COVID-19 in the ED of patients with cancer, the evaluation demonstrates that the CUAC model is feasible and an efficient model of care for the management of disease and treatment-related concerns in general. ...